Systagenix Wound Management Settles on Quincy, Mass. for Corp. HQ

The former wound care products business of J&J subsidiary Ethicon taps Quincy, Mass., for its Americas HQ; names 13-member medical advisory board.

Systagenix Wound Management, the former wound-care business of Johnson & Johnson subsidiary Ethicon, tapped Quincy, Mass., for its Americas headquarters.

The British company, which makes a suite of advanced and general wound care products, was carved out from New Jersey-based Ethicon late last year after private equity player One Equity Partners spent an undisclosed amount to snap it up.

CEO Steve Atkinson told MassDevice there were two draws that made the Boston area attractive for its North American and South American headquarters. The first, Atkinson told us, was recruiting Scott Schorer, the former CEO of now-bankrupt Innovative Spinal Technologies and the founder and CEO of healthcare e-procurement provider CentriMed. The second was the region's prominence in the medical device industry.

"[Scott]'s a very talented leader. We can't deny that was one of the reasons why Boston was attractive to us," Atkinson told us. "But on a broader level, Boston is very much one of the three hubs for medical devices, those being California, New Jersey and Boston. [Boston] tends to be where the available partner technologies are - and a lot of the talent. We knew that we would be able to recruit talented people in Boston, and making a company stronger always starts with the people."

Schorer said he's delighted to be a part of a global company with the reach and scope to positively affect patient care on a large scale.

"Systagenix is the only large company focused 100 percent on wound care. We make more than a million advanced wound care dressings a day," Schorer said. "We're helping a lot of people."

The company also announced the appointment of a 13-member medical advisory board, chaired by Systagenix medical director Robert Snyder.

You can also access the article in its original Form at:
http://www.massdevice.com/news/systagenix-wou...